Inventor · disambiguated record
Marlon Hinner
Also filed as: HINNER MARLON · HINNER MARLON J
24 granted patents·9 pending applications·62 citations·filing 2005–2024
94Inventor score
Top patents by PatentIndex Score
33 records- 0195US9884898B2Proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2017·Granted Feb 6, 2018·17 cites·20 claims
- 0292US11345728B2Specific-binding polypeptides and uses thereofPIERIS PHARMACEUTICALS GMBH·Filed 2020·Granted May 31, 2022·2 cites·14 claims
- 0389US10273275B2Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereofPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Apr 30, 2019·10 cites·20 claims
- 0488US10774119B2Specific-binding polypeptides and uses thereofPIERIS PHARMACEUTICALS GMBH·Filed 2015·Granted Sep 15, 2020·3 cites·13 claims
- 0587US10526384B2Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereofPIERIS PHARMACEUTICALS GMBH·Filed 2013·Granted Jan 7, 2020·5 cites·16 claims
- 0685US11919931B2Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3)PIERIS PHARMACEUTICALS GMBH·Filed 2021·Granted Mar 5, 2024·1 cites·6 claims
- 0782US11261221B2Proteins specific for CD137PIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Mar 1, 2022·2 cites·12 claims
- 0882US10400016B2Proteins specific for calcitonin gene-related peptidePIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Sep 3, 2019·4 cites·25 claims
- 0978US10329334B2Proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2017·Granted Jun 25, 2019·1 cites·13 claims
- 1078US10118952B2Proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2017·Granted Nov 6, 2018·1 cites·15 claims
- 1178US10072056B2Proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2017·Granted Sep 11, 2018·1 cites·18 claims
- 1278US10065998B2Proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2017·Granted Sep 4, 2018·1 cites·18 claims
- 1377US11382963B2Engineered T cells and uses thereforPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Jul 12, 2022·1 cites·5 claims
- 1475US11034737B2Proteins specific for calcitonin gene-related peptidePIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Jun 15, 2021·1 cites·17 claims
- 1575US10947284B2Fusion moleculesPIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Mar 16, 2021·1 cites·22 claims
- 1675US10316071B2Fusion moleculesSANOFI SA·Filed 2016·Granted Jun 11, 2019·2 cites·15 claims
- 1772US12195503B2Proteins specific for CD137PIERIS PHARMACEUTICALS GMBH·Filed 2022·Granted Jan 14, 2025·0 cites·17 claims
- 1871US10913778B2Anti-cancer fusion polypeptides, encoding nucleic acids and methods of using polypeptidesPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Feb 9, 2021·1 cites·33 claims
- 1971US10865250B2Anti-cancer fusion polypeptidePIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Dec 15, 2020·1 cites·8 claims
- 2069US9150629B2Human tear lipocalins which bind PCSK9 and methods of use thereofPIERIS AG·Filed 2014·Granted Oct 6, 2015·1 cites·56 claims
- 2168US2022296690A1Engineered t cells and uses thereforPIERIS PHARMACEUTICALS GMBH·Filed 2022·Application pending·0 cites
- 2266US2025163139A1Antibody that binds to vegf-a and il6 and methods of useHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 2366US2018371038A1Novel proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2018·Application pending·0 cites
- 2466US2018371037A1Novel proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2018·Application pending·0 cites
- 2566US2018346532A1Novel proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2018·Application pending·0 cites
- 2663US7611863B2Selective staining of biomembranes using voltage-sensitive dyesMAX PLANCK GESELLSCHAFT·Filed 2005·Granted Nov 3, 2009·5 cites·10 claims
- 2762US10064963B2Methods and compositions for treating disordersPIERIS AG·Filed 2013·Granted Sep 4, 2018·1 cites·8 claims
- 2860US10787491B2Nucleic acid molecules encoding muteins of human lipocalin 2 with affinity for glypican-3 (GPC3)PIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Sep 29, 2020·0 cites·11 claims
- 2960US2020148733A1Novel interleukin-17a-specific and interleukin-23-specific binding polypeptides and uses thereofPIERIS PHARMACEUTICALS GMBH·Filed 2019·Application pending·0 cites
- 3059US2021198380A1Anti-cancer fusion polypeptidePIERIS PHARMACEUTICALS GMBH·Filed 2020·Application pending·0 cites
- 3150US9598476B2Nucleic acid molecules encoding muteins of human tear lipocalin which bind PCSK9DAIICHI SANKYO CO LTD·Filed 2015·Granted Mar 21, 2017·0 cites·51 claims
- 3250US2017173112A1Novel binding proteins for pcsk9DAIICHI SANKYO CO LTD·Filed 2017·Application pending·0 cites
- 3347US2021363257A1Novel fusion protein specific for cd137 and pd-l1PIERIS PHARMACEUTICALS GMBH·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Marlon Hinner files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →